Combinations of an azole (itraconazole, voriconazole, or posaconazole) with an echinocandin (caspofungin, micafungin, or anidulafungin) were tested against 20 clinical isolates of Aspergillus flavus according to EUCAST guidelines. The interactions were determined using two endpoints-minimal effective concentration (MEC) and minimal inhibitory concentration (MIC)-via calculation of the fractional inhibitory concentration (FIC) index. A higher prevalence of synergistic interactions was observed for MIC, whereas indifference was the most frequent outcome according to MEC among the 20 strains. Combined treatment of A. flavus with these two important classes of antifungals should be explored further in in vivo studies.
Introduction
Aspergillus flavus is the etiological agent of several forms of infection in humans, from hypersensitivity reactions to invasive fungal infection. This species is the most common cause of fungal sinusitis, cutaneous infections, and endophthalmitis in tropical countries, and after A. fumigatus, is the most frequently isolated agent among patients with invasive aspergillosis. 1, 2 Azole antifungals are the first line of treatment of Aspergillus spp. infections. Voriconazole (VCZ) as the first choice, posaconazole (PCZ) mainly as prophylaxis in patients at risk, and itraconazole (ITZ) and isavuconazole are used in specific cases such as primary resistance to VCZ. 3, 4 At the same time, many cases of azole resistance have been linked to A. fumigatus, and a smaller number to A. flavus. 5, 6, 7 Echinocandins are also available for the treatment of aspergillosis and have been used in association with azoles in cases of complicated treatment. 8, 9, 10 Because both classes of antifungal agents have different therapeutic targets in the fungal cell, with echinocandins inhibiting glucan synthesis (essential for fungal cell wall formation) and azoles inhibiting the biosynthesis of ergosterol (an essential component of the fungal cell membrane), their use in combination seems to be promising. 11, 12 Because most cases of invasive aspergillosis are caused by A. fumigatus, most studies showing an interaction between azoles and echinocandins have been dealing with this species, and a few studies have explored interactions toward A. flavus. The main objective of the present study was to determine the in vitro profile of azole-echinocandin interactions against clinical isolates of A. flavus.
Methods

A. flavus strains
Twenty A. flavus strains were studied, which were recovered from patients with different forms of aspergillosis, including sinusitis and invasive and cutaneous aspergillosis, in the Laboratory of Mycological Research of the Federal University of Santa Maria, Brazil. The strains were identified by micro-and macromorphology and by sequencing of internal transcribed spacer (ITS) regions. The MasterPure yeast DNA purification kit (Epicentre R , Lucigen Corporation, Middleton, WI, USA) was used for DNA extraction, whereas amplification of the DNA fragment spanning the ITS region was performed by polymerase chain reaction (PCR) using primers ITS1 (5 -TCCGTAGGTGAACCTGCGG-3 ) and ITS2 (5 -GCTGCGTTCTTCATCGATGC-3 ) as described previously. 13 The isolates were stored at -80 
Antifungal sensitivity testing
Antifungal susceptibility of A. flavus strains was evaluated by the microdilution method following the EUCAST (European Committee on Antimicrobial Susceptibility Testing) recommendations. 14 The strains were cultivated in PDA at
35
• C until sporulation (3 to 5 days). Conidial suspensions were prepared by covering the colonies with 5 ml of distilled sterile water supplemented with 0.1% of Tween 20, and then the conidia were rubbed with a cotton swab and transferred to a sterile tube. The conidial suspensions were adjusted to a cell concentration of 2 to 5 × 10 6 conidia/ml.
A 1:10 dilution was prepared in sterile water to obtain a final suspension of 2 to 5 × 10 5 conidia/ml; 100 μl of the suspension was placed into each well of 96-well microtiter plates that contained 100 μl of antifungal drugs diluted in Rowell Park Memorial Institute (RPMI) 1640 at the final concentrations ranging from 0.063 to 32.00 mg/l for ITZ and VCZ, 0.008 to 4.00 mg/l for PCZ, and 0.001 to 8.00 mg/l for CAS, MFG, and ANF. As sterility and growth control, columns 11 and 12 of each plate were filled with RPMI plus water and RPMI plus the inoculum, respectively. The inoculum concentration was confirmed by colony counting on Sabouraud dextrose agar. The inoculated plates were incubated at 37
• C. The minimal effective concentration (MEC) of echinocandins was determined after 24 h, and the minimal inhibitory concentration (MIC) of azoles after 48 h of incubation. 14 
Antifungal interaction assays
Testing of the antifungal-drug interactions was performed in accordance with the EUCAST broth microdilution checkerboard method. 14 The final concentrations of the antifungal drugs ranged from 0.001 to 0.125 mg/l for echinocandins, 0.016 to 8.00 mg/l for ITZ, and 0.004 to 2.00 mg/l for VCZ and PCZ. Aliquots (50 μl) of the antifungal drugs four times more concentrated than the final concentration were dispensed into the microtiter plates. After that, 100 μl of the conidial suspension at the concentration of 2 to 5 × 10 5 conidia/ml, prepared as described above, was added into each well. The microplates were incubated at 37
• C. MEC and MIC readings were carried out within 24 and 48 h of incubation, respectively. All the experiments were conducted in triplicate. To assess the nature of in vitro interactions between azoles and echinocandins, the fractional inhibitory concentration (FIC) index (FICI) was 
Results
The FICI results and the interaction percentages of each azole-echinocandin combination are summarized in Table 1 while the ITZ-MFG combination showed higher prevalence of indifference, as seen for the MEC reading endpoint. For all combinations of VCZ with echinocandins, indifference was the prevalent result according to MEC, whereas according to MIC, higher prevalence of synergistic interactions was observed. For combinations VCZ-CAS, VCZ-MFG, and VCZ-ANF, the FICI ranges were 0.064-8.125, 0.039-8.125, and 0.075-31.00, respectively, according to the MEC readings, and 0.005-2.00, 0.005-1.001, and 0.004-1.002, respectively, according to MIC.
The PCZ combinations with all echinocandins also showed indifference as the most prevalent result in terms of the MEC endpoint. On the other hand, synergy was the main result when MIC was used for calculations. The FICI ranges according to the MEC endpoint were 0.038-9.625, 0.078-8.625, and 0.009-32.50 for combinations PCZ-CAS, PCZ-MFG, and PCZ-ANF, respectively. In terms of MIC, the FICI range was 0.008-2.001 for all PCZechinocandin combinations.
For all azole-echinocandin combinations, low frequency of antagonism was observed in terms of MEC readings, whereas according to the MIC endpoint, there was no antagonism.
Discussion
Although A. flavus is less prevalent than A. fumigatus among cases of invasive aspergillosis, when this species is the pathogen of this form of infection, high mortality rates are observed; furthermore, A. flavus is more virulent in terms of the ability to cause noninvasive aspergillosis. 16 Drug sensitivity studies have shown good activity of azole antifungals against clinical and environmental A. flavus strains, 17, 18 and echinocandins show good or moderate activity too against this species. 17, 19 Nevertheless, some authors have reported resistance of A. flavus to both azoles and echinocandins. 7, 20, 21 Azole-echinocandin combinations against A. flavus have been almost unexplored. In this study, we evaluated in vitro interactions of ITZ, VCZ, or PCZ with each of the echinocandins: CAS, MFG, or ANF. For all the combinations, depending on the endpoint used for calculations, the results showed synergistic or indifferent interactions with infrequent or no antagonism, when tested against 20 clinical isolates.
For the MIC endpoint, the combinations of VCZ with the three echinocandins revealed high prevalence of synergistic activity. Successful therapy with the combination of this azole and caspofungin has been reported in cases of pulmonary infection associated with paranasal sinusitis and scleritis caused by A. flavus. 22, 23 Similarly, the combined treatment with VCZ and ANF yielded prolonged survival and reduced fungal load as compared to ANF alone in a murine model of A. flavus aspergillosis. 24 The most diverse results were obtained for the combinations of echinocandins with ITZ. The ITZ-ANF combination proved to be almost exclusively synergic among the 20 clinical isolates according to MIC; the same outcome has already been reported by other authors. 25 In contrast, for MEC readings, this interaction was indifferent and revealed a significant frequency of antagonism. The combination of ITZ with CAS was mostly synergistic for both endpoints, whereas the ITZ-MFG combination was indifferent toward the majority of clinical isolates in terms of both endpoints. Shalit et al. 26 27, 28, 29, 30 however, to our knowledge, the combinations of this azole with echinocandins against A. flavus are explored for the first time in this study, showing promising results for future in vivo experiments.
The synergistic in vitro effect of azole-echinocandin combinations against A. flavus isolates depended on the endpoint. More combinations were classified as synergistic when the MIC endpoint was used rather than the MEC. This fact can be explained by the fungistatic activity of the echinocandins, since they are capable of causing alterations in the morphology of Aspergillus hyphae in very low concentrations, however for total growth inhibition (MIC) a much higher concentration is required, so the calculation of the FICI tends to synergy.
Although limited by the different endpoints interpretations, these observations encourage future evaluations of these antifungal combinations in in vivo models of infection by A. flavus.
